Valuation Update With 7 Day Price Move • Aug 11
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to ₩25,350, the stock trades at a trailing P/E ratio of 29.3x. Average trailing P/E is 9x in the Healthcare Services industry in South Korea. Total returns to shareholders of 510% over the past three years. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩17,300, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 8x in the Healthcare Services industry in South Korea. Total returns to shareholders of 341% over the past three years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩35,200, the stock trades at a trailing P/E ratio of 39.1x. Average trailing P/E is 9x in the Healthcare Services industry in South Korea. Total returns to shareholders of 713% over the past three years. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₩33,450, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 9x in the Healthcare Services industry in South Korea. Total returns to shareholders of 678% over the past three years. New Risk • May 31
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 0.5x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change). High level of non-cash earnings (44% accrual ratio). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). New Risk • May 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (45% accrual ratio). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Profit margins are more than 30% lower than last year (4.6% net profit margin). Annuncio • Apr 23
Sphere Corp. announced that it expects to receive KRW 37.5 billion in funding from History Investment Co., Ltd. Sphere Corp. has announced a private placement of Series 6 unsecured private placement convertible bonds with warrants of the company to raise gross proceeds of KRW 37,500,000,000 on April 22, 2026. The transaction involves new investor participation of History Investment Co., Ltd. for KRW 4,000,000,000, MVP Innovative Growth PEF for 25,000,000,000, KB Securities Co., Ltd. for 2,000,000,000 and other investors. The Bonds are 100% convertible into 834,650 common shares of the company at a conversion price value of KRW 44,929 and carry interest rate of 0% and maturity interest rate of 0%. The conversion billing period starts from April 30, 2027 to March 30, 2031.The transaction has been approved by the board of directors of the company. The transaction is subject to 1 year hold period. The Bonds have a maturity date of April 30, 2031. The transaction is expected to close on April 30, 2026. New Risk • Apr 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). High level of non-cash earnings (45% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (4.6% net profit margin). Shareholders have been diluted in the past year (18% increase in shares outstanding). Annuncio • Mar 13
Sphere Corp., Annual General Meeting, Mar 26, 2026 Sphere Corp., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea Annuncio • Jan 07
Sphere Corp. announced that it expects to receive KRW 25 billion in funding Sphere Corp. announced a private placement to issue 1% Series 5 Bearer Convertible Bonds with Unsecured Warrants due January 30, 2029 for gross proceeds of KRW 25,000,000,000 on January 5, 2026. The transaction will include participation from new investor Baekruta Co., Ltd.. The transaction has been approved by shareholders, expected to close on January 30, 2026, restricted to a hold period, bears 1% coupon rate, 2% maturity rate, matures on January 29, 2029, 100% convertible into 1,758,953 common shares at a fixed conversion price of KRW 14,213 from January 30, 2027 to December 30, 2028. New Risk • Dec 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (82% accrual ratio). Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Profit margins are more than 30% lower than last year (-4,415% net profit margin). Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩7,320, the stock trades at a trailing P/E ratio of 77.7x. Average trailing P/E is 8x in the Healthcare Services industry in South Korea. Total returns to shareholders of 88% over the past three years. New Risk • Nov 29
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: -4,415% Last year net profit margin: 7.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (82% accrual ratio). Shareholders have been substantially diluted in the past year (74% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Profit margins are more than 30% lower than last year (-4,415% net profit margin). Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩8,950, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 9x in the Healthcare Services industry in South Korea. Total returns to shareholders of 132% over the past three years. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩8,040, the stock trades at a trailing P/E ratio of 36.4x. Average trailing P/E is 9x in the Healthcare Services industry in South Korea. Total returns to shareholders of 121% over the past three years. New Risk • Aug 31
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (61% accrual ratio). Shareholders have been substantially diluted in the past year (113% increase in shares outstanding). Revenue is less than US$1m. Buy Or Sell Opportunity • Aug 22
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 13% to ₩11,480. The fair value is estimated to be ₩9,535, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 83% over the last year. Earnings per share has declined by 209%. New Risk • Aug 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 83% over the past year. Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Minor Risk Revenue is less than US$5m (₩3.8b revenue, or US$2.7m). Buy Or Sell Opportunity • Jul 31
Now 29% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to ₩10,900. The fair value is estimated to be ₩8,424, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 83% over the last year. Earnings per share has declined by 209%. Buy Or Sell Opportunity • Jul 09
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 41% to ₩10,360. The fair value is estimated to be ₩8,417, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 83% over the last year. Earnings per share has declined by 209%. Buy Or Sell Opportunity • Jun 17
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 31% to ₩10,310. The fair value is estimated to be ₩8,536, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 83% over the last year. Earnings per share has declined by 209%. New Risk • May 31
New major risk - Revenue and earnings growth Revenue has declined by 83% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 83% over the past year. Shareholders have been substantially diluted in the past year (131% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩3.8b revenue, or US$2.7m). Reported Earnings • Mar 20
Full year 2024 earnings released: ₩778 loss per share (vs ₩1,065 loss in FY 2023) Full year 2024 results: ₩778 loss per share. Net loss: ₩13.6b (loss widened 22% from FY 2023). Annuncio • Mar 11
LifeSemantics Corp., Annual General Meeting, Mar 25, 2025 LifeSemantics Corp., Annual General Meeting, Mar 25, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 406, teheran-ro, gangnam-gu, seoul South Korea Annuncio • Mar 07
LifeSemantics Corp. announced that it has received KRW 15 billion in funding from Widwin Investment Co., Ltd. On March 7, 2025, LifeSemantics Corp. closed the transaction. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩6.9b revenue, or US$4.8m). Market cap is less than US$100m (₩90.4b market cap, or US$62.0m). Annuncio • Jan 01
LifeSemantics Corp. announced that it has received KRW 4.30251 billion in funding On December 30, 2024, LifeSemantics Corp. closed the transaction. New Risk • Nov 28
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ₩6.9b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (99% increase in shares outstanding). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (₩6.9b revenue, or US$5.0m). Market cap is less than US$100m (₩71.7b market cap, or US$51.4m). Annuncio • Oct 22
LifeSemantics Corp. has completed a Follow-on Equity Offering in the amount of KRW 999.99768 million. LifeSemantics Corp. has completed a Follow-on Equity Offering in the amount of KRW 999.99768 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 387,596
Price\Range: KRW 2580
Transaction Features: Subsequent Direct Listing Annuncio • Apr 19
LifeSemantics Corp. announced that it expects to receive KRW 2.000001535 billion in funding LifeSemantics Corp. announced a private placement to issue 997,507 common shares at an issue price of KRW 2,005 per share for the gross proceeds of KRW 2,000,001,535 on April 17, 2024. The transaction will include participation from individual investor Seungjae Song. The transaction has been approved by the shareholders and is restricted to a hold period and is expected to close on May 7, 2024. Annuncio • Feb 29
An undisclosed buyer agreed to acquire 10.04% stake in Medistaff Co., Ltd. from LifeSemantics Corp. (KOSDAQ:A347700) for KRW 1.2 billion. An undisclosed buyer agreed to acquire 10.04% stake in Medistaff Co., Ltd. from LifeSemantics Corp. (KOSDAQ:A347700) for KRW 1.2 billion on February 28, 2024. The consideration consists of KRW 1217.9 million in cash. As part of the consideration, KRW 1217.9 million was paid towards common equity. The transaction is expected to complete on March 6, 2024. New Risk • Jan 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩30.5b market cap, or US$22.7m). New Risk • Jan 02
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 39% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (₩2.8b revenue, or US$2.1m). Market cap is less than US$100m (₩35.6b market cap, or US$27.2m). Annuncio • Dec 08
LifeSemantics Corp. has completed a Follow-on Equity Offering in the amount of KRW 10.900303 billion. LifeSemantics Corp. has completed a Follow-on Equity Offering in the amount of KRW 10.900303 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 5,436,560
Price\Range: KRW 2005
Discount Per Security: KRW 30.075
Transaction Features: Rights Offering New Risk • Sep 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 39% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (₩2.8b revenue, or US$2.1m). Market cap is less than US$100m (₩45.1b market cap, or US$34.0m). New Risk • Sep 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 39% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (₩2.8b revenue, or US$2.1m). Market cap is less than US$100m (₩48.0b market cap, or US$36.2m). 
